Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Sanofi
With
Genzyme, a Sanofi Company
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Metastatic hormone refractory prostate cancer defined as those patients with evidence of progression of disease in spite of castrate levels of testosterone indicated by rising levels of PSA
No previous chemotherapy although those patients that have received estramustine can enter the study provided the estramustine was stopped 3 weeks before dosing of study drug
screening PSA values \>20ng/ml. this must be confirmed by two separate measurements at least 2 weeks apart
You may not be if
Treatment within 4 weeks before randomization and/or whilst on study, treatment with the following: 1)non-approved or experimental drug, 2)treatment with a drug with similar mechanism of action to ZD6474
concurrent treatment with other anticancer agents, othr than docetaxel and prednisolone as defined in the protocol
Clareo Health | E3-Hormone Refractory Prostrate Cancer Taxotere Combination
